Immune Profiling During Ocrelizumab Treatment in Multiple Sclerosis
Latest Information Update: 29 Jan 2021
At a glance
- Drugs Ocrelizumab (Primary)
- Indications Multiple sclerosis
- Focus Pharmacodynamics
- 25 Jan 2021 Status changed from recruiting to completed.
- 12 Jul 2017 Status changed from not yet recruiting to recruiting.
- 05 May 2017 New trial record